Hospital ICUs lean on telemedicine amid U.S. COVID-19 crisis

By Chad Terhune

(Reuters) – As the coronavirus pandemic spreads deeper into America’s small towns and rural outposts, Dr. Tallulah Holmstrom has seen familiar faces fill her intensive-care unit in Camden, South Carolina.

A native of this hamlet of 7,000 people, Holmstrom saw its ICU threatened with closure in recent years as specialists departed for bigger cities. Now faraway doctors are helping treat the community’s COVID-19 patients, thanks to technology.

KershawHealth, the local hospital, installed cameras and other equipment for 24-hour monitoring by a company that employs doctors and nurses remotely. Sitting in cubicles in St. Louis, Houston and Honolulu, as well as other countries including Israel and India, these medical workers watch patients’ vital signs on computer screens and talk to local staff on two-way video about medications and treatments. KershawHealth employees can summon emergency help from these teleworkers by hitting a button on the wall.

Holmstrom said those changes, begun four years ago, have helped her hospital better handle the current crisis. While Camden and surrounding Kershaw County have seen more than 1,600 confirmed infections and 34 deaths, the technology has enabled many of the area’s COVID-19 patients to be hospitalized close to home.

“Now a patient can look up from their ICU bed here and they are seeing a friend’s daughter or son taking care of them or someone they go to church with,” said Holmstrom, chief medical officer at KershawHealth.

Camden is among a growing number of communities relying on this elaborate form of telemedicine to cope with an unrelenting COVID-19 case load and to manage unpredictable surges.

Well before the current crisis, vast stretches of rural America lacked easy access to advanced medical care. More than 130 rural hospitals have closed in the United States since 2010, including 18 last year, according to University of North Carolina researchers.

Rural areas tend to have higher rates of underlying health conditions such as diabetes and hypertension. Their populations often are older and poorer – making them more vulnerable to COVID-19.

Even if beds were available, qualified staff are hard to find. It’s estimated that 43 states, including South Carolina, face a shortage of highly trained ICU doctors, known as intensivists, according to researchers at George Washington University. These shortages may worsen with hospitalizations in many states predicted to peak this fall, when the coronavirus mixes with flu season, according to Patricia Pittman, director of the university’s Mullan Institute for Health Workforce Equity.

“No one is suggesting telemedicine is ideal, but it’s probably one of the least bad options,” she said. “It is definitely better than having no one and helicoptering people out.”

SCALING EXPERTISE

About a third of U.S. hospitals surveyed in 2017 said they had access to a formal program of telemedicine for critically ill patients. Studies have shown telemedicine can benefit ICU patients by promoting the best practices supported by medical evidence and by reducing complications. During the pandemic, doctors say, it has helped conserve personal protective equipment and reduce workers’ exposure to the virus.

There can be drawbacks, too, if physicians try to monitor too many people at once, which can lead to poor decisions or even medical errors. Tele-ICU generally requires physicians working remotely to hold a license in each state where people are hospitalized.

The Trump administration has eased rules on telehealth during the pandemic and expanded reimbursement by Medicare. Shares of telemedicine companies such as Teladoc Health Inc have soared as patients embraced online visits.

Sutter Health, a large hospital system in California, said it manages more than 300 ICU beds across 18 hospitals from offices in Sacramento and San Francisco.

Earlier this month at its Sacramento hub, Dr. Vanessa Walker checked in remotely on a patient who was taken off a ventilator earlier in the day at Sutter’s Roseville hospital about 25 miles away. Using a headset and camera, she clicked the patient’s name on her screen, which rang a doorbell to notify the patient that she was entering the room via video.

“Save your breath. You’re doing well otherwise,” she told the patient.

Walker, the medical director of Sutter’s electronic ICU for its hospitals in California’s Central Valley, had a wide array of information across six monitors at her desk. She could review medical records and see multiple scans of the patient’s lungs before and after treatment.

CAUTIONARY TALE

As use of this technology grows, patient-safety advocates warn hospitals not to cut corners. They say cameras and computers are no substitute for trained professionals at the bedside who can respond rapidly to life-threatening complications.

The Leapfrog Group, a nonprofit that monitors patient safety, recommends that a physician certified in critical care medicine perform an in-person review of each ICU patient daily before handing off monitoring to colleagues remotely. The group says remote doctors should lower their patient loads if they can’t respond within five minutes to requests from on-site staff and evaluate the patient.

Steve Burrows, a Los Angeles filmmaker, remains a skeptic.

He said his mother had complications during a hip operation in 2009 and suffered permanent brain damage in surgery and the ICU at a Wisconsin hospital.

In litigation, Burrows said, he learned that a doctor was remotely monitoring more than 150 ICU patients, and there was no physician in the ICU who could respond to his mother’s low blood pressure. He released an HBO documentary, “Bleed Out,” in 2018 about his mother’s case.

“Telemedicine is fantastic if it’s used properly,” he said in an interview. “But I think replacing doctors at the bedside with technology is insane.”

At trial, a jury found there was no negligence by the hospital. Advocate Aurora Health, the current hospital owner after a merger, said its electronic ICU “does not replace bedside caregivers. Instead, it serves as an additional set of eyes that provides an extra layer of safety.”

‘CONSTANT ATTENTION’

Advanced ICU Care, the St. Louis company serving Camden, works with more than 90 hospitals in 26 states. Overall, it has treated more than 1,300 COVID-19 patients.

“These patients need constant attention and continuous adjustments. That is a lot of what we do,” said Dr. Ram Srinivasan, the company’s chief medical officer.

South Carolina remains a hot spot for coronavirus infections with more than 126,000 cases and 2,877 confirmed deaths as of September 11.

The state’s first two cases of COVID-19 were announced the same day in early March and one was in Camden, a place so rural that signs remind people not to ride horses on the sidewalk.

Holmstrom, the chief medical officer at KershawHealth, got a call with the news while driving home that Friday, March 6. Within a matter of days, there were six people infected and four were hospitalized.

The Camden ICU was nearly full for weeks as the medical staff juggled COVID-19 patients alongside the normal flow of critically ill people. Hospitalizations eased around Memorial Day, Holmstrom said, only to surge again in July and much of August.

“When you’re a town this small and 32 people get sick in one day that’s a lot,” said Vic Carpenter, Kershaw County administrator.

Holmstrom, who was born in the hospital where she now works, has experienced highs and lows. A close friend who spent six weeks in the hospital is now back to full strength. Holmstrom arranged final video calls for others to say goodbye to their families.

KershawHealth is bracing for another surge this fall, when it once again will turn to remote doctors to back up busy hospital staff.

“It’s like someone constantly in the background overlooking everything with your care,” Holmstrom said.

(Reporting by Chad Terhune in Los Angeles; Additional reporting by Nathan Frandino in Sacramento; Editing by Marla Dickerson)

Exclusive: U.S. hospitals turn down remdesivir supplies, limit use to sickest COVID-19 patients

By Deena Beasley

(Reuters) – U.S. hospitals have turned down about a third of their allocated supplies of the COVID-19 drug remdesivir since July as need for the costly antiviral wanes, according to unpublished government statistics provided to Reuters by a U.S. pharmacists’ group.

Some hospitals said they are still buying the Gilead Sciences medicine to build inventory in case the pandemic accelerates over the winter. But they said current supplies are adequate, in part because they are limiting use to severely ill patients.

The Food and Drug Administration has allowed more liberal remdesivir use, but 6 out of 8 major hospital systems contacted by Reuters said they were not using it for moderate cases.

The slowdown suggests that a shortage of the drug is over and threatens Gilead’s efforts to expand use of remdesivir, which it sells under the brand name Veklury in some countries.

The U.S. Department of Health and Human Services (HHS) told hospitals and other healthcare organizations on Friday that between July 6 and September 8, state and territory public health systems accepted about 72% of the remdesivir they were offered, Michael Ganio, senior director of pharmacy practice and quality at the American Society of Health-System Pharmacists, told Reuters.

Hospitals in turn took only about two-thirds of what states and territories accepted, he added. It was not immediately clear what happened to the surplus supplies.

Neither Gilead nor HHS immediately responded to requests for comment.

A surplus of remdesivir – which costs $3,120 for a 6-vial intravenous course – marks a turnaround from earlier in the pandemic, when supplies of the drug had fallen short of demand in some regions.

Government-led distribution of remdesivir will expire at the end of September. Hospitals said they have little information on availability after that.

Remdesivir was first authorized by the FDA in May for emergency use in COVID-19 patients hospitalized and on oxygen support after data showed that it helped shorten hospital recovery time.

The agency last month expanded use to hospitalized patients who do not require oxygen support, based on data published in the JAMA medical journal showing that the drug provided a modest benefit for those patients.

The newer data has left many experts unconvinced.

Dr. Aneesh Mehta, chief of infectious diseases services at Atlanta’s Emory University Hospital, said Emory is focusing supplies on patients likely to benefit the most.

“I am not terribly impressed with the study,” said Dr. Adarsh Bhimraj, an infectious disease specialist at the Cleveland Clinic. He said he remains “skeptical” about using remdesivir in patients with moderate COVID, especially given the price.

(Reporting By Deena Beasley; editing by Peter Henderson and Bill Berkrot)

Mexico nears 70,000 official COVID-19 deaths, but toll likely far higher

MEXICO CITY (Reuters) – The confirmed coronavirus death toll in Mexico is primed to hit 70,000 when official data is released on Friday, a grim milestone for a country among those most affected by the pandemic.

Making matters worse, excess mortality data from mid-March through early August indicates that the total number of deaths beyond the official count is likely tens of thousands higher.

The spread of the virus has ravaged an already ailing economy, which is now seen contracting by up to 13% this year, the deepest recession since the 1930’s-era Great Depression.

On Thursday, the health ministry announced that 652,364 infections and 69,649 deaths have been attributed to the strain of the coronavirus that was first detected late last year in China.

Based on official data, Mexico is the nation with the fourth highest number of deaths globally, and the 13th highest on a per capita basis, according to a tally by Johns Hopkins University.

But earlier this month, the health ministry said it recorded more than 120,000 “extra” deaths from mid-March through August 1. The measure compares mortality figures this year with a four-year average from 2015 to 2018.

Brazil remains No. 1 in Latin America, the region with the most infections globally, for both confirmed coronavirus cases and deaths. It has posted a total of 4.2 million infections and more than 128,000 deaths so far.

In a sliver of good news, the rate of new cases in Peru, Colombia and Mexico has fallen slightly in recent weeks.

Overall, more than 900,000 people have died worldwide from the pandemic, with the deadliest outbreaks in the United States, Brazil, India and Mexico.

(Reporting by David Alire Garcia; Editing by Tom Brown)

U.S. CDC reports 191,353 deaths from coronavirus

(Reuters) – The U.S. Centers for Disease Control and Prevention (CDC) on Friday reported 6,381,013 cases of the new coronavirus, an increase of 37,451 cases from its previous count, and said that the number of deaths had risen by 1,091 to 191,353.

The CDC reported its tally of cases of the respiratory illness known as COVID-19, caused by a new coronavirus, as of 4 p.m. ET on Sept. 10 versus its previous report a day earlier.

The CDC figures do not necessarily reflect cases reported by individual states.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Maju Samuel)

Swiss add Paris, Vienna to list of areas for coronavirus quarantine

ZURICH (Reuters) – Switzerland has added the regions around Paris and Vienna to its list of areas with high COVID-19 infection rates requiring incoming travelers to enter quarantine for 10 days.

The government said it was adopting a regional approach for neighboring countries for the measures which will come into force on Sept. 14. As part of this, it named Ile de France and the Vienna region as areas with a raised risk of infection.

The government also put the Czech Republic and all of Spain on its list of entire countries with a quarantine requirement, which already includes the United States,  India and Brazil.

“It is not a good idea to go to high-risk areas,” Health Minister Alain Berset told a media conference, advising Swiss travelers to steer clear of places on the list.

Switzerland, which has had quarantine restrictions since July 6, said it was responding to a spike in infection numbers in the country.

Switzerland reported 528 new cases of the coronavirus on Friday, the highest daily rise in infections since early April.

As part of its new approach, the government said only regions of neighboring countries where the infection rate is above its limit of 60 cases per 100,000 people will be added to the list, rather then the entire country.

Border regions may be exempted from the list to take into account the close interaction with neighboring regions, it said.

Thousands of workers cross Switzerland’s borders with France, Germany and Italy daily to work in Geneva, Basel and the southern canton of Ticino.

(Reporting by John Revill; Editing by Michael Shields)

U.S. CDC reports 190,262 deaths from coronavirus

(Reuters) – The U.S. Centers for Disease Control and Prevention (CDC) said on Thursday the number of deaths due to the new coronavirus had risen by 1,115 to 190,262 and reported 6,343,562 cases, an increase of 32,899 cases from its previous count.

The CDC reported its tally of cases of the respiratory illness known as COVID-19, caused by a new coronavirus, as of 4 pm ET on Sept. 9 versus its previous report a day earlier.

The CDC figures do not necessarily reflect cases reported by individual states.

(Reporting by Trisha Roy in Bengaluru; Editing by Ramakrishnan M.)

Philippines presidential spokesman links pardon of U.S. Marine to vaccine access

MANILA (Reuters) – Philippine President Rodrigo Duterte’s decision to pardon a United States Marine convicted of killing a transgender woman nearly six years ago may have stemmed from his desire to get access to coronavirus vaccines being developed by U.S. firms, his spokesman said on Thursday.

“His decision didn’t surprise me. Why? Because I know he is upholding the higher national interest”, Harry Roque said in a regular news briefing when asked to give his “personal take” on the president’s move.

Duterte on Monday pardoned Lance Corporal Joseph Scott Pemberton who was serving a six- to 10-year sentence for killing Jennifer Laude near a former U.S. navy base in 2014, sparking condemnation from activists who described the move as a “mockery of justice”.

Roque, who served as lawyer in the prosecution of Pemberton, had likened Laude’s killing to the “death of Philippine sovereignty”.

“I think this pardon, although this is my personal opinion, was to ensure Filipinos would benefit from a vaccine against COVID-19 should the Americans develop one,” Roque said. “I don’t see any problem with that”.

The Philippines, among a number of developing countries with large populations keen to secure a supply a COVID-19 vaccine, met with representatives of U.S. drugmaker Pfizer Inc last week.

U.S. public health officials and Pfizer said a COVID-19 vaccine could be ready for distribution in the United States as soon as next month

Duterte has pledged that the country, which has the most coronavirus infections and second largest number of COVID-19 deaths in Southeast Asia, would be “back to normal” by December, pinning his hopes on access to affordable vaccines from countries like China and Russia.

The Southeast Asian nation, which has more than 248,000 confirmed COVID-19 cases, plans to buy 40 million doses worth $400 million for 20 million people, about a fifth of its 107 million population.

(Reporting by Karen Lema; editing by Philippa Fletcher)

Senate panel to take up FAA aircraft certification reform bill

By David Shepardson

(Reuters) – The U.S. Senate Commerce Committee on Sept. 16 will hold a hearing to consider a bill to strengthen U.S. oversight of aircraft certification following two fatal Boeing Co. 737 MAX crashes.

The measure seeks to eliminate the ability of aircraft makers like Boeing to unduly influence the certification process. It marks the most significant step toward reforms following the 2018 and 2019 crashes in Indonesia and Ethiopia that killed 346 people and sparked demands to change how the Federal Aviation Administration (FAA) approves new airplanes.

Boeing and the FAA did not immediately comment.

U.S. Senate Commerce Committee chair Roger Wicker, a Republican, and ranking member Maria Cantwell, a Democrat, introduced the proposal in June that would grant the FAA new power over the long-standing practice of delegating some certification tasks to aircraft manufacturer employees. It would give the agency authority to hire or remove Boeing employees conducting FAA certification tasks and allow the FAA to appoint safety advisers.

Boeing is still working to win regulatory approvals to resume commercial service of its 737 MAX since the plane was grounded worldwide in March 2019, plunging the Chicago-based company into a crisis since compounded by the COVID-19 pandemic.

Boeing also faces lawsuits and an ongoing criminal probe.

The Senate legislation would grant new whistleblower protections to workers at airplane and parts manufacturers. It would also require the FAA to create a new safety reporting system for employees to detail concerns anonymously.

While victims’ family members applauded proposed reforms, they are also demanding that critical aircraft systems – like the MCAS flight control system linked to both crashes – be approved by the FAA, not just Boeing, and that manufacturers be required to re-certify new aircraft derived from earlier models.

Representative Peter DeFazio, who chairs the House Transportation and Infrastructure Committee, told Reuters in July he planned to introduce FAA certification reform legislation in September, saying the Senate bill was a good start but did not go far enough.

(Reporting by David Shepardson, Editing by Franklin Paul and Chizu Nomiyama)

Germans fear Trump more than coronavirus, survey shows

BERLIN (Reuters) – Germans are more afraid of the policies of U.S. President Donald Trump than of the coronavirus which has wreaked havoc on Europe’s biggest economy, an annual survey of German attitudes showed on Thursday.

Fears that Trump’s policies would make the world a more dangerous place eclipsed economic worries, with 53% of those asked putting him top of their list, according to the survey conducted in June and July for the R+V Insurance Group.

Rising living costs, the economic situation and the cost to taxpayers of European Union debt came second, third and fourth for traditionally cautious Germans.

The coronavirus took 17th spot and only around a third of those asked said they were concerned that they or someone they knew well would get COVID-19.

Germany has kept the number of COVID-19 cases and deaths relatively low compared with some of its European neighbors, but new infections are rising again.

The survey did not give details on which aspects of Trump’s policies worried Germans but R+V quoted political scientist Manfred Schmidt of the Ruprecht-Karls-University in Heidelberg as blaming his foreign policy.

“Particularly notable are the trade-war-like conflicts with China and trade and security policy attacks against allies, including Germany. In addition, the withdrawal of the United States from international cooperation and the confrontation with Iran,” said Schmidt who advises R+V on the annual survey.

Some 2,400 people were questioned for the “Fears of Germans” survey, which has been conducted since 1992.

(Reporting by Madeline Chambers, editing by Emma Thomasson and Catherine Evans)

U.N.’s Guterres calls for $35 billion more for WHO COVID-19 program

ZURICH (Reuters) – United Nations Secretary General Antonio Guterres called for $35 billion more, including $15 billion in the next three months, for the World Health Organization’s (WHO) “ACT Accelerator” program to back vaccines, treatments and diagnostics against COVID-19.

Some $3 billion has been contributed so far, Guterres told an online event on Thursday, calling it “seed funding” that was less than 10% of what the WHO wants for the program, formally called Access to COVID-19 Tools (ACT) Accelerator.

Financial support has, so far, lagged goals, as nations or governments including the European Union, Britain, Japan and the United States reach bilateral deals for vaccines, prompting Guterres and WHO General Director Tedros Adhanom Ghebreyesus to plead to nations to contribute.

“We now need $35 billion more to go from ‘start up’ to ‘scale up and impact’,” Guterres said in online remarks at a meeting of a council formed to help the ACT Accelerator gain traction. “There is real urgency in these numbers. Without an infusion of $15 billion over the next three months, beginning immediately, we will lose the window of opportunity.”

European Commission President Ursula von der Leyen pledged backing, having in August already promised 400 million euros ($474 million) to the COVAX vaccine portion of the program.

“It is difficult to find a more compelling investment case. The European Commission will remain deeply and entirely committed to the success of the ACT Accelerator,” von der Leyen said. “The world needs it, we all need it.”

Tedros renewed calls for scaling up COVID-19 clinical trials. AstraZeneca this week suspended late-stage trials on its potential vaccine after an illness in a participant in Britain. Chief Executive Pascal Soriot said on Thursday if safety reviewers allow a restart, the company should still know by year’s end if its vaccine works.

(Reporting by John Miller; Editing by Michael Shields)